SPERO THERAPEUTICS, LLC. Cambridge, MA, USA
Spero’s lead program, SPR741, also called Potentiator, is a platform approach to combination therapy to treat multi-drug resistant Gram-negative infections, such as Enterobacteriaceae and Acinetobacter baumannii, including carbapenem-resistant strains. SPR741 increases the spectrum and potency of more than two dozen classes of Gram-positive antibiotics to include activity against multidrug resistant Gram-negative infections when used in combination. As a part of the CARB-X program, Spero will be screening antibiotic partners for SPR741, with the goal of identifying at least one partner to take through Phase 1 clinical trials.
Current Development Stage: Phase 1
CARB-X Investment: Initial investment of up to $1.6m with potential option payments up to $5.4m
Initial CARB-X Investment Date: April 1, 2017
Graduation Date: March 31, 2018